<DOC>
	<DOCNO>NCT01264731</DOCNO>
	<brief_summary>The purpose study determine 1 ) safety administration topical 5 % imiquimod cream without administration peptide-based vaccine patient cutaneous metastasis melanoma 2 ) evaluate whether topical imiquimod site melanoma metastasis , without vaccine , increase ) endothelial expression E-selectin b ) T cell infiltration .</brief_summary>
	<brief_title>Combination Therapy Topical Imiquimod Plus Multipeptide Vaccination Cutaneous Metastases Melanoma</brief_title>
	<detailed_description>Primary goal : Safety : 1 ) To determine safety administration topical 5 % imiquimod cream without administration peptide-based vaccine patient cutaneous metastasis melanoma . Biologic effect : 1 ) To evaluate whether topical imiquimod site melanoma metastasis , without vaccine , increase ) endothelial expression E-selectin b ) T cell infiltration . Secondary goal : 1 . To assess whether T cell infiltrate melanoma metastasis imiquimod , without vaccination , reactive peptide vaccine . 2 . To evaluate whether topical imiquimod decrease proportion FoxP3+ CD25hi CD4+ cell ( putative regulatory T cell , Tregs ) among tumor infiltrate T cell . 3 . To estimate effect vaccine CXCR3 , CLA , activation marker expression circulate tumor-infiltrating antigen-experienced CD4 CD8 T cell . 4 . To obtain preliminary data clinical response cutaneous metastasis melanoma propose combination regimen . 5 . To determine expression TLR7 immune cell and/or melanoma cell metastatic melanoma microenvironment . 6 . To obtain preliminary data association metastatic melanoma T cell infiltration pattern ( immunotypes ) molecular clinical response imiquimod . Design : The present proposal clinical trial associate correlative study bring together several observation unmet scientific clinical need promise new effective immunotherapy melanoma metastasis . This open-label two-cohort , nonrandomized , pilot study combination topical imiquimod plus systemic vaccination MELITAC 12.1 vaccine , emulsion mixture 12 class I MHC-restricted melanoma peptide ( 12-MP ) class II MHC-restricted tetanus toxoid helper peptide ( tet ) . Cohort 1 receive combination imiquimod + vaccine ; Cohort 2 receive imiquimod . Patients eligible cohort 1 eligible vaccine base HLA type clinical factor . Cohort 2 patient eligible vaccine . Primary Endpoints : Safety : 1 ) Toxicity profile topical imiquimod site melanoma , without MELITAC 12.1 vaccine . Biologic effect : 1 ) Change level intratumoral E-selectin infiltrating TCD4 TCD8 lymphocytes : 1. pretreatment v vaccine + imiquimod ; 2. vaccine vs. without vaccine ( cohorts 1 v 2 ) ; 3. lesion imiquimod vs. without imiquimod . Secondary Endpoints : The follow evaluate compare pretreatment vaccine + imiquimod , compare finding patient without vaccine ( cohorts 1 2 ) , well lesion without imiquimod . 1 . Change number vaccine-reactive T cell melanoma metastasis , determine ELIspot tetramer analysis . 2 . Change percentage FoxP3+ CD25hi CD4+ ( putative regulatory T cell , Tregs ) among tumor infiltrate T cell determine immunohistochemistry flow cytometry . 3 . Expression CXCR3 , CLA , activation marker ( CD69 , CD137 , HLA-DR , CD27 CD28 ) vaccine-reactive cell blood within melanoma metastasis immunohistochemistry flow cytometric analysis . 4 . TLR7 expression cell metastatic melanoma microenvironment . 5 . Changes T cell infiltration pattern metastasis ( immunotype ) The following evaluated post-treatment 6 . Clinical regression individual imiquimod-treated untreated metastasis</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Participants stage IIIB , IIIC IV melanoma cutaneous metastasis . 2 . Patients must adequate cutaneous metastasis melanoma readily accessible biopsy provide minimum 0.3 cm3 tissue per biopsy ( approximately 0.85 cm 0.85 cm x 0.85 cm five 2mm core biopsy ) three time point . Several scenario may fulfill tumor burden requirement . For example , patient may one large lesion core biopsy take first second biopsy time point entire lesion excise final tissue sample . Other combination acceptable . 3 . The intent limit study patient cutaneous melanoma metastasis rather subcutaneous lymph node metastasis imiquimod may penetrate deep metastasis . 4 . Patients may multiple primary melanoma . 5 . Patients may may metastasis cutaneous primary site , mucosal primary site , ocular primary site , unknown primary site . 6 . Patients brain metastasis may eligible meet follow criterion Patients le equal 5 metastasis may eligible long follow 3 criterion true : The brain metastases completely remove surgery treat completely stereotactic radiotherapy . Stereotactic radiotherapy , gamma knife , use 1 week prior study entry . There evident growth brain metastasis since treatment . No metastasis great 2 cm time protocol entry Patients great 5 metastasis may eligible 3 criterion meet least one year elapse since last treatment . 7 . All participant must ECOG performance status 0 1 ability willingness give inform consent 8 . Patients must least one intact axillary and/or inguinal lymph node basin . A patient prior lymph node biopsy may candidate lymphoscintigraphy demonstrate intact drainage node basin . A lymphoscintigram may perform screen ensure drainage regional node plan vaccine site . If lymphoscintigram perform sentinel lymph node locate , patient ineligible study vaccine sit available . 9 . Laboratory parameter follow : The follow laboratory parameter require participant . If lab value appear error result transient treatable condition , investigator use his/her clinical judgment decide test may repeat . The requirement inclusion follow : HLAA1 , A2 , A3 , A11+ ANC &gt; 1000/mm3 Platelets &gt; 100,000/mm3 Hgb ≥ 9 g/dL HGBA1C &lt; 7 % AST ALT ≤ 2.5 x upper limit normal ( ULN ) Bilirubin ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN HIV negative ( within 6 month study entry ) Hepatitis C negative ( within 6 month study entry ) LDH 2 x ULN 10 . Patients must 18 year old study entry 1 . Patients brain metastasis unless meet criterion outline 2 . Patients currently receive systemic cytotoxic chemotherapy , radiation , experimental therapy , receive therapy within precede 4 week . Gamma knife stereotactic radiosurgery may administer within prior 4 week , must administer less one week prior study enrollment . Patients currently receive nitrosoureas receive therapy within precede 6 week . 3 . Patients eligible clinically detectable melanoma deem likely investigator require intervention first 12 week study would require premature discontinuation . Examples circumstance may include untreated bone metastasis risk fracture , rapidly progressive low volume disease . 4 . Patients know suspected allergy component vaccine . 5 . Patients receive follow medication study entry within precede 4 week exclude : Agents putative immunomodulating activity ( exception nonsteroidal antiinflammatory agent topical steroid Allergy desensitization injection . Systemic corticosteroid , administer parenterally orally . Inhaled steroid ( e.g . Advair® , Flovent® , Azmacort® ) permit . Topical corticosteroid acceptable , include steroid low solubility administer nasally local effect ( e.g . Nasonex® ) . Any pharmacologic growth factor ( e.g . GMCSF , GCSF , erythropoietin ) . Interferon therapy . Interleukin2 interleukins . Topical 5 % Imiquimod cream : Patients must imiquimod therapy body site within 4 week study entry must prior imiquimod therapy lesion treat , watch biopsied present study . If imiquimod use past either lead complete regression treat lesion , lesion remove surgically , patient may eligible . 6 . Prior melanoma vaccination may exclusion criterion som circumstance : Patients recur progressed either administration melanoma vaccine may eligible enroll 12 week follow last vaccination . Patients may vaccinate previously peptide vaccine ( include MELITAC 12.1 similar vaccine ) nonpeptide vaccine . 7 . Pregnancy possibility become pregnant vaccine administration . Female patient childbearing potential must negative pregnancy test ( urinary serum betaHCG ) prior administration first vaccine dose . Males female must agree , consent form , use effective birth control method course vaccination . Women must also breast feeding . This consistent existing standard practice vaccine chemotherapy protocol . 8 . Patients medical contraindication potential problem complying requirement protocol , opinion investigator . 9 . Patients classify accord New York Heart Association classification Class III IV heart disease ( Appendix 4 ) . 10 . Patients body weight &lt; 110 lbs amount frequency blood drawn 11 . Participants must prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement . Participants active autoimmune disorder require therapy also exclude . The following exclusionary : The presence laboratory evidence autoimmune disease ( e.g . positive ANA titer ) without associate symptom Clinical evidence vitiligo Other form depigmenting illness Mild arthritis require NSAID medication medical therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>peptide vaccine</keyword>
	<keyword>aldara</keyword>
	<keyword>imiquimod</keyword>
	<keyword>immunotherapy</keyword>
</DOC>